Tenon Medical, Inc. Announces Adjournment of Special Meeting of Stockholders Tenon Medical, Inc. Meeting adjourned to Monday

Meeting adjourned to Monday, January

8, 2024 at 1:30pm Pacific Time

LOS GATOS, CA / ACCESSWIRE / December 22,

2023 / Tenon Medical, Inc. ("Tenon" or the "Company") (NASDAQ:TNON), a company transforming care for patients

suffering with certain sacroiliac joint disorders, today announced that the December 21, 2023 Special Meeting of Stockholders was adjourned

to January 8, 2024 at 1:30pm Pacific Time to provide additional time to obtain stockholders' votes on Proposal 2, approval of an amendment

of the Certificate of Incorporation. For additional information, please refer to the proxy statement previously filed by the Company with

the Securities and Exchange Commission ("SEC") on November 22, 2023.

Importantly, the record date for the stockholders

to vote at the Special Meeting remains the close of business on November 9, 2023 (the "Record Date"). Stockholders who have

previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action. Stockholders as

of the Record Date can vote, even if they have subsequently sold their shares.

Tenon's Board of Directors recommends you

vote in support of Proposal 2. Since Proposal 2 requires an affirmative vote of a majority of the outstanding shares for passage, by not

responding with your vote you are essentially opposing this proposal. Therefore, we urge our stockholders who have not yet executed their

vote to please do so.

You may use one of the options below to ensure

that your vote is promptly recorded in time for the Special Meeting:

About Tenon Medical, Inc.

Tenon Medical, Inc., a medical device company

formed in 2012, has developed The Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using

a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal

planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the

Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest

cortical bone. Since the national launch of the Catamaran SI Joint Fusion System in October 2022 Tenon is focused on three commercial

opportunities with its System in the SI Joint market which includes: 1) Primary SI Joint procedures, 2) Revision procedures of failed

SI Joint implants and 3) SI Joint fusion adjunct to a spine fusion construct. For more information, please visit https://www.tenonmed.com/.

The Tenon Medical logo, Tenon Medical and

Catamaran are registered trademarks of Tenon Medical, Inc.

Forward Looking Statements

This press release contains "forward-looking

statements," which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates

will or may occur in the future. Forward-looking often contains words such as "intends," "estimates," "anticipates,"

"hopes," "projects," "plans," "expects," "seek," "believes," "see,"

"should," "will," "would," "target," and similar expressions and the negative versions thereof.

Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors

it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain

and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements

as a result of various factors. For details on the uncertainties that may cause our actual results to be materially different than those

expressed in our forward-looking statements, please review our Annual Report on Form 10-K for the fiscal year ended December 31, 2022

on file with the Securities and Exchange Commission at www.sec.gov, particularly the information contained in the section entitled "Risk

Factors". We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future

events or otherwise unless required by law.

Shannon Devine / Rory Rumore